 |
ARM Holdings
Speciality Scanners
BP
Nyota Minerals
The ReThink Group
Serabi Mining
Sutherland Healthcare Group
Motive Television
DIRECTOR DEALINGS
|
 |
Monday 8th February
Economics: EU Sentix Investor Confidence.
Final results: Amino Technologies. BATM Advanced Communications and St Modwen Properties.
Interim results: Kofax.
AGMs/EGMs: Collins Stewart
Tuesday 9th
Economics: UK BRC Retail Sales Monitor, UK RICS House Price Balance, UK Manufacturing Production, UK Industrial Production and US Wholesale Inventories.
Interim results: British Land.
Final results: Alphameric, Patsystems and Wolfson Microelectronics.
Trading statements: United Drug.
AGMs/EGMs: Energi Oil, Hardide, Tui Travel and Victrex.
Wednesday 10th
Economics: UK Nationwide Consumer Confidence, UK BRC Shop Price Index, BoE Governor Mervyn King speaks, UK BoE Inflation Report, US Trade Balance, US Crude Oil Inventories and US Federal Budget Balance.
Final results: Telecity Group and Travis Perkins.
Interim results: BHP Billiton, CSR, Elan Corporation, Hargreaves Lansdown, Morse and Smurfit Kappa.
AGMs/EGMs: Andor Technology, Care UK, Daily Mail and General Trust, Grainger, Impax Group, Nasstar, Payzone, Petropavlovsk, Pressure Technologies, Renovo Group and UK Commercial Property.
Thursday 11th
Economics: EU ECB Monthly Bulletin, US Core Retail Sales, US Retail Sales, US Unemployment Claims, US Business Inventories and US Natural Gas Storage.
Final results: Catlin Group, Minorplanet Systems, Rolls-Royce Group and Smith & Nephew.
Interim results: BT Group, Diageo and Rio Tinto.
Trading statements: Halma, Sports Direct and Thomas Cook.
AGMs/EGMs: Customvis, Greencore Group, The Paragon Group of Companies and Zytronic.
Friday 12th
Economics: UK PPI Input, UK PPI Output, EU Flash GDP, EU Industrial Production, UK CB Leading Index, US Preliminary University of Michigan (UoM) Consumer Sentiment and US Preliminary UoM Inflation Expectations.
Trading statements: Micro Focus International and Shaftesbury.
AGMs/EGMs: Lupus Capital and Shaftesbury.
|
 |
|
|
Smartphones use more chips
Last year was a tough time for the semiconductor industry, but chipmaker ARM Holdings put in a good performance, gaining market share. Despite a 20% industry-wide fall in dollar revenues, final results revealed that the Company ended the year with dollar revenues just 10% lower. Pre-tax profits were down by 4% at £96.8m and earnings per share suffered a similar percentage fall to 5.45p; but the board demonstrated its confidence in the future by increasing the full year dividend by 10% to 2.42p, a move which speaks volumes. The real highlight of the fourth quarter was the growth in mobile applications. Certainly the opportunity for ARM looks to be increasing with the demand for smartphones and already the first ARM technology-based mobile computers have been introduced. Rumour has it that ARM is the supplier for the Apple's new multi-functional iPad, the recently unveiled half-inch thick gadget that has been designed for a variety of media uses, including videos, games and electronic books. ARM sells around 2.4 chips per phone, as the complexity of mobile phones increases and in recent months, the Company has signed a total of six processor licences for mobile phones and computer applications.. Warren East, CEO, commented that “..The Company is well-placed for this strong performance to continue as leading semiconductor manufacturers are increasingly designing ARM technology into their products, and as ARM technology becomes ever more pervasive in markets with long-term growth such as smartphones, digital TVs and microcontrollers. Recently, Infineon and STMicroelectronics have announced the intention to use, for the first time, ARM processors in their smartcard and digital TV/set-top box product lines respectively.”
Commercialising technology
Sadly, despite major advances in medicine over the past thirty years, breast cancer still remains a killer. Speciality Scanners has developed a breast-only magnetic resonance (MR) scanner for breast cancer management. There seem to be obvious potential here, as the Company was awarded a £1.6m Technology Strategy Board Grant, and this sort of money is not handed out lightly. Today, we believe the Company is on the doorstep of the turning those technologies into commercial success. When the final results were announced in late January, the board was able to reassure investors that growing interest had been shown in the commercialisation of the Company's proprietary MR scanner technologies by major international medical equipment manufacturers. The directors are in discussions with several institutions operating in the healthcare sector about the commercialisation and roll-out of the Company's Clinical Assessment & Treatment Service (CATS). In addition, there is also increasing interest in collaborating on the Company's award winning, New Products R&D Programme, which includes a real time MRI-guided Biopsy System and Tumour Ablation System. These sorts of technologies would allow image guided diagnostic and treatment procedures to be integrated into a single outpatient session, instead of repeated hospital visits over several months. It does seem that these technologies widen the product portfolio and ought to enhance future revenue generation potential.
Below expectations
With the demise of the banks, something like 10% of all dividend income paid to pension funds by FTSE 100 companies comes from BP; and so the performance of the oil giant affects millions. The announcement of final results saw the share price drift lower, as the market seemed disappointed by fourth quarter figures where profits came in at 5% below the consensus forecast. That all seems to be a bit tough as in 2009, BP had put in a cracking performance and even in that last "disappointing" quarter saw underlying replacement cost profit rise by 70% to $4.38bn. After a 4% increase in production in 2009, guidance provided to analysts, is that production in 2010 will be slightly lower, which is probably about 3% less than most brokers had been forecasting; but production growth is expected to resume in 2011. The fourth quarter dividend was maintained at 14 cents, which due to changes in the exchange rate, works out at 8.679p i.e. 12% lower than the amount paid in 2008. The board see no let up in the pressure on downstream margins, as they believe that the recovery in the leading economies in US and Europe will be slow and gradual. Refining margins are a problem for the whole industry; it has been estimated that two leading US oil companies, Chevron and Exxon, are losing something like $7m a day between them turning crude oil into downstream products. It now becomes clear that BP needs an oil price of between $60 and $65 a barrel to cover capital expenditure and to keep on paying the dividend. But all in all, the stock trades on a prospective PE of 7.6 times coupled with a decent yield.
Positive pre-scoping study
The management team at Nyota Minerals knows the value of good newsflow. The Company seems to be making rapid progress with the Tulu Kapi Gold Project in Ethiopia, which it got its hands on following the low-priced acquisition of Minerva Resources last year. The results of a pre-scoping study and metallurgical tests have just been announced, which indicated that Tulu Kapi would be economically viable. The pre-scoping study was basically a desktop study that was completed by Venmyn Rand (Pty), an internationally recognised South Africa mining consultancy, to see if the project was feasible. The study was prepared as a "Preliminary Assessment" under the NI 43-101, the Canadian mineral resource classification system. Apparently the most likely mining scenario is an open pit mine, with early indications that, what the board term a "Big Pit" mining scenario, may be feasible. During the year, additional resource drilling is planned, which has the potential to increase the reserves of the project; as Venmyn believes that the immediate exploration focus ought to be upgrading the current Mineral Resource model. One of the study’s key conclusions was that regionally there was evidence suggesting the existence of a much larger gold field within the greater Tulu Kapi/Ankore licence area. Metallurgical testwork on a 300kg sample achieved recoveries in excess of 95%; which Melissa Sturgess, CEO, suggests will mean that “...when Tulu Kapi commences production, we will be able to build a low cost processing plant to extract the gold from ore.”
Confounds the sceptics
Recruitment business The ReThink Group is making amends for the poor interim results that were announced in September when pre-tax profits were shown to have slumped by 85% to £12,000, even though gross revenue was 18% higher at £24.6m. At the time, a big improvement was predicted for the second half. Well, it looks like ReThink has confounded City sceptics, as the board now expects to report pre-tax profits in the region of £300,000, when the full-year figures are announced in early April. The news is that, this positive recovery in the second half, stemmed from a strong performance both in the Group’s permanent recruitment business and also at the recruitment process outsourcing division (ReThink Professional Services). Certainly, the board is optimistic about revenue growth for the rest of the year, as this period has started well with the number of contractors on assignment already ahead of management expectations, together with a continued positive demand for permanent recruitment services. 
Well funded exploration strategy
Exploring for gold in the area surrounding an existing gold mine looks like a shortcut to success. That's what Serabi Mining is up to at its Palito Gold Project in northern Brazil. At the moment, the Company is involved in small scale mining of the free-digging surface oxide deposit, where the ore does not need to be crushed before being processed by the existing Carbon in Pulp plant. The underground part of the Palito mine has been mothballed due to past problems that led to insufficient ore being blocked out to continue mining. That said, the mine has produced 110,000 gold equivalent ounces since 2005 and has a gold equivalent JORC resource of 660,000 ounces, of which 187,000 ounces is the reserve category at a grade of 7.3g/t gold. Recently, Serabi laid out its exploration plans, which show how it will be spending the £2.25m raised in December. The board is seeking to expand the project’s hard rock resource to more than 1.5 million ounces. The plan of work over the coming months, is to carry out geophysics on the first ten anomalies plus geophysical interpretation, which is to be followed by diamond drilling of these anomalies between July and September.
NHS supplier raising cash
Shareholders in Sutherland Healthcare Group have an opportunity to top up their holding by way of a private placing. The supplier of patient hygiene and sexual health products to the National Health Service is seeking to raise up to £250,000 at 2.5p. Small company share tipster Tom Winnifrith's Worship Street Investments will be subscribing for £100,000 worth of new shares and Sutherland's Chairman John French has agreed to invest at least £10,000. The funds raised will be used to launch new product lines and also hire a full time sales person.
More problems at Motive
Motive Television announced on 23 December 2009, its strategy of closing down or selling its television production businesses to focus on digital terrestrial television technology sector. The Company has now announced that an administrator had been appointed at its 50.6%-owned subsidiary Scarlett Television. The board is apparently negotiating the sale of its remaining television production businesses which are Motive Television Ltd and Brown Eyed Boy Ltd. Trading in the shares of Motive Television were suspended on 4th January 2010 as the Company did not have a Nomad; and it now looks likely that the shares risk becoming delisted.
In's and Out's from the Bridge Hall CFD Desk
Another volatile week is behind us!!!
The market is sitting on a knife edge currently and any minor economic news is causing nervous investors to react accordingly. Traders and dealers were closing their end of month positions off, until Monday when the Manufacturing Purchasing Index jumped to 56.7 against Decembers 54.6. Is the recovery gaining momentum after the MPI rose at its fastest rate in fifteen years?
These figures lay the ground for an uncertain week ahead, the market absorbed these figures and took the lift that came with it but it should be noted that often, market cycles will create short term uncertain trends. These market conditions would prove to the experienced investor/trader that sometimes, you are better off on the sidelines awaiting clearer more fundamental trends. On the back of the economic news, we took a very cautious stance running through the week.
To start the week, we closed off some short positions that we let run throughout the weekend. BSKYB was the first trade of the week for us, awaiting the news of their results was key to this one, along with good technical levels. We followed that with a pairs trade in Astrazeneca (AZN.L) and Smith and Nephew (SN.L), that we also let run through the main bulk of the week. BAE Systems (BA.L), Morrisons Supermarkets (MRW.L), BP (BP.L) were the other trades we ran alongside the bulk of our pairs trading, the latter’s results proving to be far worse than expected, but from that, it gave us good buying opportunities. We were also strongly involved with BG Group (BG.L) this week, trying to scalp a small profit in the run up to the announcements of their results.
We are expecting this week to start off from the lead of the US Non Farm Payroll figures which come out on Friday (5th Feb) at 13:30pm. These are a major market mover and give the market clear direction for traders to attach themselves to. Following that, on Tuesday this week, we have a raft of economic data i.e. UK BRC Retail Sales Monitor, UK RICS House Price Balance, UK Manufacturing Production, UK Industrial Production and the US Wholesale Inventories. These could well be a key driver as to how the remainder of the forthcoming week pans out.
With volatility abounding there are opportunities appearing in the market, but with every piece of minor data, there is an air of caution to be considered. The real danger of some small peripheral European Economies is being exposed and this fear is weighing very strongly on the market. Bearish attitudes are appearing more and more, as the low five thousands in the FTSE beckons. Some market cheer may be needed shortly to fight the support level into the high four thousands.
Happy trading this week and we'll be in touch again next week for another update.
To subscribe for your FREE CFD Morning Call via e-mail, covering our latest market long/short recommendations and to find out more about our services, click here, alternatively call our CFD desk on 0207 337 9711 or e-mail cfddesk@bridgehall.co.uk.

Featured stocks
ARM Holdings (ARM)
FTSE100
Share price: 205p
12 months high-low: 205p – 82.75p
Market value: £2.6bn
www.arm.com
BP (BP.)
FTSE 100
Share price: 580p
12 months high-low: 639p – 400p
Market value: £108.9bn
www.bp.com
Motive Television (MTV)
AIM
Share price: 0.38p suspended
12 months high-low: 0.88p – 0.25p
Market value: £1.30m
www.motivetelevision.co.uk
Nyota Minerals (NYO)
AIM
Share price: 10.5p
12 months high-low: 11.5p – 2.5p
Market value: £23.79m
www.nyotaminerals.com
The ReThink Group (RTG)
AIM
Share price: 7.5p
12 months high-low: 13.5p – 4p
Market value: £6.83m
www.therethink-group.com
Serabi Mining (SRB)
AIM
Share price: 1.63p
12 months high-low: 4.88p – 0.38p
Market value: £5.34m
www.serarbimining.com
Speciality Scanners (SCAN)
PLUS
Share price:
12 months high-low: 3.125p – 1.25p
Market value: £1.34m
www.specialityscanners.com
Sutherland Health Group (SHGP)
PLUS
Share price: 2.75p
12 months high-low: 3p – 2.25p
Market value: £1.51m
www.sutherlandhealth.com
Directors dealings
Directors dealings can provide a useful insight
Director buys
Blavod Wines & Spirits (BES) 128,205 @ 3.9p
Connaught (CNT) 2 directors 155,000 @ 317p – 331p
ITM Power (ITM) 104,156 @ 19.65p
Legal & General Group (LGEN) 20.238 @ 77p
Maxima Holdings (MXM) 2 directors 20,860 @ 81.5p
Murgitroyd Group (MUR) 3,000 @ 265p
NCC Group (NCC) 5,000 @ 423p
Ovoca Gold (OVG) 200,000 @ 19p
Sanderson Group (SND) 10,761,801 @ 20p
Sportingbet (SBT) 4 directors 114,756 @ 69.7p
Sunkar Resources (SKR) 35,595 @ 25.75p
Thwaites (Daniel) (THW) 5,000 @ 150p
Director sells
M.P. Evans Group (MPE) 2 directors 545,506 @ 340p
IG Group Holdings (IGG) 200,000 @ 404.5p
Mitchells & Butlers (MAB) 4,213 @ 280p
Red Rock Resources (RRR) 1,000,000 @ 1.3p
The above list of transactions represents a selection of the directors' buys and sells reported last week
Written by Dr Michael Green - Independent analyst – DOC Investments Limited – doc@docinvest.co.uk
|
|
|